Glaukos Corporation’s GKOS growth prospects are supported by the continued expansion of interventional glaucoma, growing clinical and commercial synergies between iDose TR and iStent infinite, and

Celanese Corporation CE is shifting production from its Engineered Materials compounding facility in Ulsan, South Korea, to its plants in Nanjing and Shenzhen, China, and Silvassa, India. The move

ICON plc ICLR is moving through a credibility and earnings reset that is now as much about controls as it is about demand. The company has laid out the scope of its accounting findings, flagged

American Tower AMT shares have risen 10.5% in the year-to-date period compared with the industry’s 9.0% growth.

This Zacks Rank #3 (Hold) company is well-positioned to benefit from long-term growth

Block’s XYZ Cash App, the popular peer-to-peer payment platform, is introducing a new way to pay with the launch of Cash App Tags. These NFC-enabled physical payment accessories allow customers to

Teladoc Health, Inc. TDOC is a pioneer and global leader in the telemedicine industry. It has a broad international presence, serving clients, supporting medical operations and reaching members

Agenus AGEN is taking an uncommon route to validate demand for its lead immuno-oncology combination, botensilimab plus balstilimab (BOT+BAL), before a traditional launch. Instead of waiting for full

Agenus AGEN sits at a classic biotech crossroads. On one side is BOT+BAL, a lead immuno-oncology program being tested in a late-stage setting where current checkpoint inhibitors have historically

Agenus AGEN centered its investment case on botensilimab plus balstilimab (BOT+BAL), a checkpoint combination being advanced in refractory microsatellite stable (MSS)/mismatch repair proficient